National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Eribulin (Halaven®) for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.

Rapid Review

Commenced Completed Outcome
09/02/2011 March 2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation  

Commenced Completed Outcome
26/09/2012 07/12/2012 Reimbursement not recommended at the submitted price.

The NCPE believe that, at the submitted price, eribulin (Halaven®) is not cost effective for the treatment of patients with locally advanced breast cancer or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.

Eribulin (Halaven®) Summary

December 2014

The HSE has approved reimbursement following confidential price negotiations.